Medical Affairs

Assessing how to continue ensuring scientific exchange and provide valuable education for healthcare providers?

RESOURCES

Ensuring an Open Channel with Regulatory and Medical Policy Opinion Leaders During COVID

Many companies, particularly new entrants into the U.S. pharma arena, are facing some level of disruption or impact on their projected timelines for seeking FDA licensure, gathering data from trials for filing, conducting health economics analyses needed to demonstrate improved outcomes, or conducting real-world evidence studies that can help inform medical societies’ deliberations on clinical […]

View

Assessing and managing issues around clinical trials: a multi-stakeholder approach

Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.

View

How the pandemic provides opportunities to evolve traditional medical education activities into modern learning solutions

While initial impressions may be that the COVID-19 pandemic is creating a barrier for medical education initiatives, this is not necessarily the case across the board.

View

Unlocking virtual medical congresses

Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.

View

No two virtual congresses are the same

Each congress has a different structure to its overall program and method in delivering its scientific information, despite stating that they all plan to keep to the traditional congress format.

Download PDF

Get in Touch

We know there are numerous considerations when it comes to the impact of COVID-19 on clinical trials and what this means for your organization. We are here to help.